Back to all studies
Not Yet RecruitingNCT07052058

Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

This not yet recruiting study focuses on depression and currently lists sites or participation links in Brazil.

DepressionBiologicalFrom 18 Years to 65 Years
In plain English

Key information made simple

This study exists to compare options and see whether the medication Tocilizumab offers something meaningfully different. Researchers are trying to understand what the medication Tocilizumab could change in day-to-day care and decision-making. For people living with Depression, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Hospital de Clínicas de Porto Alegre in Porto Alegre. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. Common reasons not to take part include pregnancy or breastfeeding and other factors that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Interested?

Check my eligibility

Study reference: NCT07052058. Your email is the only field you need to provide here.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Brazil.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com